Cigna Group

Cigna Group (CI) — Investment Memo

🐂 The Bull Case (Warren's voice)

We aren't buying an insurance company; we are buying a toll booth on the American healthcare highway.

• The "Plumbing" Moat: Evernorth isn't just a service; it is the infrastructure. When a company integrates Cigna’s pharmacy benefit management (PBM) and clinical services, ripping it out is surgical trauma. The switching costs are immense.
• The Float Engine: Like our beloved GEICO, the insurance arm provides a steady stream of float. While the net margins look thin on the P&L, the cash flow is the heartbeat. They collect premiums upfront and pay claims later.
• The Pivot to Services: The shift from "paying claims" (Healthcare) to "managing care" (Evernorth) is the key. Services have stickier revenue and higher quality earnings than the volatile underwriting of insurance.
• The Essentiality: Healthcare spending is the ultimate non-discretionary expense. As the population ages, the volume of claims increases. Cigna doesn't need to "innovate" to win; they just need to exist as the middleman.
• Attractive Entry: This becomes a Berkshire-grade asset when the price reflects a utility rather than a growth stock. If we can buy it at a significant discount to its cash-generating power, the thin margins are a feature (keeping competitors away), not a bug.

🐻 The Bear Case (Charlie inverts)

Let's look at where the corpse is buried. This business is a house of cards built on a 2% margin.

• The Regulatory Guillotine: The PBM model (Evernorth) is a political target. If the government mandates "transparent pricing" or caps PBM rebates, the "plumbing" doesn't just leak—it bursts. This is a structural threat that no amount of "optimization" can fix.
• The Margin Fragility: A net margin of 1.4% to 2.2% is an absolute joke. In a business this size, a 1% swing in medical loss ratios (MLR) or a slight miscalculation in reserves doesn't just hurt earnings—it wipes them out. It is a high-wire act without a net.
• Growth by Ledger: Revenue jumped from $153.6B to $274.9B, but earnings didn't follow the same trajectory. That is "empty calories" growth. They are buying revenue to mask a lack of organic brilliance. Buying growth is the fastest way to destroy capital.
• The Most Likely Death: Federal intervention in PBMs. Timeline: 2–5 years. The political appetite for "fixing" pharmacy costs is at an all-time high. If the revenue model of Evernorth is legislated away, the valuation craters.

💰 Valuation & Margin of Safety

The DCF tells us what it's worth in a vacuum; the Margin of Safety tells us if we can sleep at night.

• Intrinsic value estimate: $392.72 per share.
• 25% margin of safety entry: $294.54 (Conservative: protects against mild regulatory headwinds).
• 50% margin of safety entry: $196.36 (Buffett's ideal: protects against a total PBM collapse).
• Current Status: Fairly valued to slightly cheap relative to the DCF, but dangerously expensive relative to the fragility of the margins. We are paying for a "moat" that the government might fill in with concrete.

Verdict: WATCH

The intrinsic value is there, but the margin of safety is missing. We cannot ignore the extreme fragility of a 2.2% net margin in a politically charged industry. We wait for a regulatory panic to drive the price toward $290 before committing capital.